Bianka Karge

TL;DR: Gold complexes with N-heterocyclic carbene (NHC) ligands represent a promising class of metallodrugs for the treatment of cancer or infectious diseases, and antibacterial screening of the gold complexes showed a particularly high activity against Gram-positive strains, reflecting their high dependence on an intact Trx/TrxR system.

TL;DR: A pH‐stat fed‐batch process for the production of cis, cis‐muconate from benzoate was developed, in which the addition of benzoates was coupled to the acidification of the medium to prevent overdoses of benzosate.

TL;DR: The rhodium(i) NHC derivative represents a multi-target compound with promising anti-cancer potential and acted as both a mammalian and an E. coli thioredoxin reductase inhibitor.

TL;DR: A series of gold(i) complexes with two N-heterocyclic carbene ligands (biscarbene gold complexes) were prepared and evaluated for their effects against cancer cells and pathogenic bacteria and indicated a strong correlation between cellular bioavailability and antiproliferative effects.

TL;DR: The novel (NHC)2Au+ complex exhibits substantially lower protein binding in combination with a strongly enhanced cytotoxic activity and represents a substantially improved and selective TrxR inhibitor compared to close structural analogues.